Syncom Formulations (India) Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Net profit of Syncom Formulations (India) rose 69.08% to Rs 7.00 crore in the quarter ended December 2023 as against Rs 4.14 crore during the previous quarter ended December 2022. Sales rose 13.52% to Rs 65.14 crore in the quarter ended December 2023 as against Rs 57.38 crore during the previous quarter ended December 2022.

Powered by Capital Market - Live News

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 14 February 2024.

Powered by Capital Market - Live News

Syncom Formulations (India) Ltd rose 5.22% today to trade at Rs 13.31. The S&P BSE Healthcare index is up 0.82% to quote at 29821.15. The index is up 9.16 % over last one month. Among the other constituents of the index, Artemis Medicare Services Ltd increased 4.07% and Vijaya Diagnostic Centre Ltd added 3.07% on the day. The S&P BSE Healthcare index went up 26.41 % over last one year compared to the 6.06% surge in benchmark SENSEX.

Syncom Formulations (India) Ltd has added 67% over last one month compared to 9.16% gain in S&P BSE Healthcare index and 3.12% rise in the SENSEX. On the BSE, 8.53 lakh shares were traded in the counter so far compared with average daily volumes of 21.69 lakh shares in the past one month. The stock hit a record high of Rs 13.65 on 24 Nov 2023. The stock hit a 52-week low of Rs 4.55 on 28 Mar 2023.

Powered by Capital Market - Live News

Net profit of Syncom Formulations (India) rose 81.34% to Rs 6.51 crore in the quarter ended September 2023 as against Rs 3.59 crore during the previous quarter ended September 2022. Sales rose 17.16% to Rs 63.84 crore in the quarter ended September 2023 as against Rs 54.49 crore during the previous quarter ended September 2022.

Powered by Capital Market - Live News